MedTrace Logo

Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination

NCT00143780 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2008-04-16

No results posted yet for this study

Summary

Streptococcus pneumoniae, also known as Pneumococcus, is a common cause of pneumonia in transplant patients. There has been a vaccine available for this infection called Pneumovax. Recently, a new vaccine for this infection called Prevnar has been developed which may be more effective. Vaccinating the bone marrow donor before transplant may boost the recipient's immune response to the vaccine after transplant. This study is done to compare how vaccinating the donor with one of the vaccines will affect the recipient's immune system response to the vaccine.

Conditions

  • Bone Marrow Transplant

Interventions

BIOLOGICAL

The polysaccharide vaccine used is Pneumovax (Merck vaccines)

BIOLOGICAL

The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)

Sponsors & Collaborators

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Deepali Kumar, BSc, MSc, MD, FRCP(C) · University Health Network, Toronto

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143780 on ClinicalTrials.gov